This study aimed to assess the impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical course and in determination of the treatment outcome in DLBCL patients treated with R-CHOP, considering disease-free survival (DFS) and overall survival as primary end points, and complete remission (CR) rate and treatment related toxicity as secondary end points. Here, IL18 is linked to diffuse large B-cell lymphoma.